Related Experiment Video
Updated: Jan 25, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
The Continuing Threat of Methicillin-Resistant Staphylococcus aureus
1Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary. gajdacs.mario@pharm.u-szeged.hu.
Abstract:
Staphylococcus aureus has been an exceptionally successful pathogen, which is still relevant in modern age-medicine due to its adaptability and tenacity. This bacterium may be a causative agent in a plethora of infections, owing to its abundance (in the environment and in the normal flora) and the variety of virulence factors that it possesses. Methicillin-resistant S. aureus (MRSA) strains-first described in 1961-are characterized by an altered penicillin-binding protein (PBP2a/c) and resistance to all penicillins, cephalosporins, and carbapenems, which makes the β-lactam armamentarium clinically ineffective. The acquisition of additional resistance determinants further complicates their eradication; therefore, MRSA can be considered as the first representative of multidrug-resistant bacteria. Based on 230 references, the aim of this review is to recap the history, the emergence, and clinical features of various MRSA infections (hospital-, community-, and livestock-associated), and to summarize the current advances regarding MRSA screening, typing, and therapeutic options (including lipoglycopeptides, oxazolidinones, anti-MRSA cephalosporins, novel pleuromutilin-, tetracycline- and quinolone-derivatives, daptomycin, fusidic acid, in addition to drug candidates in the development phase), both for an audience of clinical microbiologists and infectious disease specialists.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) is a persistent pathogen causing diverse infections. This review details MRSA
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Staphylococcus aureus is a highly adaptable pathogen responsible for numerous infections.
- Methicillin-resistant S. aureus (MRSA), identified in 1961, exhibits resistance to beta-lactam antibiotics due to altered penicillin-binding protein (PBP2a/c).
- MRSA represents a significant challenge as a multidrug-resistant bacterium, complicating treatment and eradication efforts.
Purpose of the Study:
- To provide a comprehensive review of MRSA, covering its history, emergence, and clinical manifestations.
- To summarize current advancements in MRSA screening, typing methodologies, and therapeutic strategies.
- To offer insights for clinical microbiologists and infectious disease specialists regarding MRSA management.
Main Methods:
- Literature review based on 230 references.
- Synthesis of historical data on MRSA emergence and evolution.
- Compilation of current knowledge on MRSA epidemiology, diagnostics, and treatment.
Main Results:
- MRSA infections are categorized into hospital-, community-, and livestock-associated types.
- Current therapeutic options include lipoglycopeptides, oxazolidinones, specific cephalosporins, and other agents like daptomycin and fusidic acid.
- Novel drug candidates are under development to combat MRSA resistance.
Conclusions:
- MRSA remains a critical global health threat due to its adaptability and resistance.
- Effective screening, typing, and a range of therapeutic options are essential for managing MRSA infections.
- Ongoing research into new antimicrobial agents is crucial for future treatment strategies against MRSA.
More Related Videos
Related Concept Videos
Stereotype Threat and Self-fulfilling Prophecies
Threats to Biodiversity
Resistivity
Resistance
Continuing Care
Continuity Equation
The mass flow rate is expressed as:

